Inventor · disambiguated record
Pamela Pavco
Also filed as: PAVCO PAMELA · PAVCO PAMELA A
21 granted patents·40 pending applications·1,088 citations·filing 1995–2021
97Inventor score
Files withSIRNA THERAPEUTICS INC23RXI PHARMACEUTICALS CORP8PHIO PHARM CORP7RIBOZYME PHARM INC5KHVOROVA ANASTASIA2
Top patents by PatentIndex Score
61 records- 0199US7176304B2RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)MCSWIGGEN JAMES·Filed 2004·Granted Feb 13, 2007·187 cites·2 claims
- 0298US10633654B2Modified RNAi polynucleotides and uses thereofPHIO PHARM CORP·Filed 2018·Granted Apr 28, 2020·32 cites·20 claims
- 0398US9938530B2RNA interference in skin indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted Apr 10, 2018·25 cites·19 claims
- 0498US9303259B2RNA interference in skin indicationsRXI PHARMACEUTICALS CORP·Filed 2013·Granted Apr 5, 2016·46 cites·12 claims
- 0598US8664189B2RNA interference in skin indicationsKHVOROVA ANASTASIA·Filed 2009·Granted Mar 4, 2014·60 cites·2 claims
- 0697US10913948B2RNA interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2018·Granted Feb 9, 2021·21 cites·7 claims
- 0797US10662430B2RNA interference in ocular indicationsPHIO PHARM CORP·Filed 2018·Granted May 26, 2020·14 cites·19 claims
- 0897US9340786B2RNA interference in dermal and fibrotic indicationsKHVOROVA ANASTASIA·Filed 2011·Granted May 17, 2016·49 cites·20 claims
- 0996US10184124B2RNA interference in ocular indicationsRXI PHARMACEUTICALS CORP·Filed 2015·Granted Jan 22, 2019·23 cites·14 claims
- 1096US9963702B2RNA interference in dermal and fibrotic indicationsRXI PHARMACEUTICALS CORP·Filed 2016·Granted May 8, 2018·23 cites·20 claims
- 1196US6566127B1Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptorRIBOZYME PHARM INC·Filed 1999·Granted May 20, 2003·141 cites·5 claims
- 1296US6346398B1Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptorRIBOZYME PHARM INC·Filed 1996·Granted Feb 12, 2002·245 cites·23 claims
- 1395US7034009B2Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)CHIRON CORP·Filed 2002·Granted Apr 25, 2006·49 cites·20 claims
- 1495US6818447B1Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptorSIRNA THERAPEUTICS INC·Filed 2000·Granted Nov 16, 2004·49 cites·12 claims
- 1594US10815485B2RNA interference in skin indicationsPHIO PHARM CORP·Filed 2018·Granted Oct 27, 2020·8 cites·5 claims
- 1693US11584933B2RNA interference in ocular indicationsPHIO PHARM CORP·Filed 2020·Granted Feb 21, 2023·2 cites·20 claims
- 1791US11001845B2Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)PHIO PHARM CORP·Filed 2016·Granted May 11, 2021·7 cites·6 claims
- 1890US10131904B2Modified RNAi polynucleotides and uses thereofPAVCO PAMELA A·Filed 2009·Granted Nov 20, 2018·23 cites·8 claims
- 1985US5731295AMethod of reducing stromelysin RNA via ribozymesRIBOZYME PHARM INC·Filed 1995·Granted Mar 24, 1998·59 cites·2 claims
- 2072US2021261968A1Rna interference in dermal and fibrotic indicationsPHIO PHARM CORP·Filed 2021·Application pending·0 cites
- 2170US2006292691A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 2270US2007004667A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 2368US2006247429A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 2468US2006287266A1RNA interference mediated ihibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 2568US2006217336A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 2667US5612215AStromelysin targeted ribozymesRIBOZYME PHARM INC·Filed 1995·Granted Mar 18, 1997·19 cites·166 claims
- 2767US2005227937A1Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptorSIRNA THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 2867US2009170197A1Nucleic Acid-Mediated Treatment of Diseases or Conditions Related to Levels of Vascular Endothelial Growth Factor Receptor (VEGF-R)SIRNA THERAPEUTICS INC·Filed 2008·Application pending·0 cites
- 2965US2006281175A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3065US2006275903A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3163US2006217337A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3263US2006247428A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3363US2006217335A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3463US2006217334A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3560US2005148530A1RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 3655US2011251258A1Rnai constructs and uses thereofRXI PHARMACEUTICALS CORP·Filed 2009·Application pending·0 cites
- 3754US2005267058A1RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)SIRNA THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 3853US2009131360A1Tripartite RNAi constructsRXI PHARMACEUTICALS CORP·Filed 2008·Application pending·0 cites
- 3952US2015105445A1RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)SIRNA THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4052US2005054596A1RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)Filed 2004·Application pending·0 cites
- 4152US2005075304A1RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)Filed 2004·Application pending·0 cites
- 4251US2007203333A1RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)MCSWIGGEN JAMES·Filed 2003·Application pending·0 cites
- 4350US2007042029A1Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)SIRNA THERAPEUTICS INC·Filed 2005·Application pending·0 cites
- 4450US2005020525A1RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 4550US2005176024A1RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2004·Application pending·0 cites
- 4649US2004220128A1Nucleic acid based modulation of female reproductive diseases and conditionsSIRNA THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 4749US2004138163A1RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)Filed 2003·Application pending·0 cites
- 4848US2004102389A1Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)RIBOZYME PHARM INC·Filed 2002·Application pending·0 cites
- 4947US2004142895A1Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathwaySIRNA THERAPEUTICS INC·Filed 2003·Application pending·0 cites
- 5047US2004127446A1Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replicationFiled 2003·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Pamela Pavco files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →